| 1 |
Chahin A, Opal SM. Severe pneumonia caused by legionella pneumophila：Differential diagnosis and therapeutic considerations[J]. Infect Dis Clin North Am, 2017, 31(1): 111-121.
|
| 2 |
Simonovich VA, Burgos PL, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia[J]. N Engl J Med, 2021, 384(7): 619-629.
|
| 3 |
严锡祥，郑爱东，张振恩，等. 重症肺炎患者肺复张治疗中不同体位对血流动力学的影响[J]. 医学临床研究，2020, 17(11): 1647-1649, 1653.
|
| 4 |
Xie Y, Du J, Jin W, et al. Next generation sequencing for diagnosis of severe pneumonia: China, 2010-2018[J]. J Infect, 2019, 78(2): 158-169.
|
| 5 |
Chen HH, Shaw DM, Petty LE, et al. Host genetic effects in pneumonia[J]. Am J Hum Genet, 2021, 108(1): 194-201.
|
| 6 |
Cho JC, Zmarlicka MT, Shaeer KM, et al. Meropenem/vaborbactam，the first carbapenem/beta-Lactamase inhibitor combination[J]. Ann Pharmacother, 2018, 52(8): 769-779.
|
| 7 |
He L, He A, Qian Y. Imipenem-resistant pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review[J]. Ann Palliat Med, 2021, 10(1): 810-817.
|
| 8 |
Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: The LEAP 2 randomized clinical trial[J]. JAMA, 2019, 322(17): 1661-1671.
|
| 9 |
Li Y, Zhu D, Peng Y, et al. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia[J]. Curr Med Res Opin, 2021, 37(4): 693-701.
|
| 10 |
Meng X, Yang B, Suen WC. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome[J]. Innate Immun, 2018, 24(1): 4-10.
|
| 11 |
Kunkler B, Salamango D, Debruine ZJ, et al. CUL5 is required for thalidomide-dependent inhibition of cellular proliferation[J]. PLoS One, 2018, 13(5): 196760.
|
| 12 |
陈 静，孙 建，冯晓丽，等. 重症肺炎患者血清CD40L、VCAM-1、sTREM-1水平与病情和预后的关系[J]. 北华大学学报(自然科学版), 2020, 21(6): 775-778.
|
| 13 |
Venkataraman R, Gopichandran V, Ranganathan L, et al. Mortality prediction using acute physiology and chronic health evaluation Ⅱ and acute physiology and chronic health evaluation IV scoring systems: Is there a difference？[J]. Indian J Crit Care Med, 2018, 22(5): 332-335.
|
| 14 |
中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志，2018, 41(4): 255-280.
|
| 15 |
李 娥，吕佳杰. 莫西沙星与头孢哌酮钠舒巴坦钠治疗老年重症肺炎的联合疗效[J]. 西南国防医药，2016, 26(3): 252-254.
|
| 16 |
徐元平，杨 辉，魏继红，等. 重症肺炎临床特点及其并发抗生素相关性腹泻的临床分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 472-474.
|
| 17 |
Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment[J]. J Investig Med, 2018, 66(6): 957-965.
|
| 18 |
Elabbadi A, Turpin M, Gerotziafas GT, et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia[J]. Infection, 2021, 49(3): 559-562.
|
| 19 |
Hang Y, Chen Y, Xue L, et al. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation[J]. Int J Antimicrob Agents, 2018, 51(3): 484-487.
|
| 20 |
王 薇，田 蓉，王 真，等. 胸腺五肽辅助比阿培南对老年重症肺炎患者肺功能及血清SP-A及SP-D水平的影响[J]. 中国老年学杂志，2020, 40(18): 3874-3877.
|
| 21 |
Sippola S, Haijanen J, Gronroos J, et al. Effect of oral moxifloxacin vs intravenous ertapenem plus oral levofloxacin for treatment of uncomplicated acute appendicitis: The APPAC Ⅱ randomized clinical Trial[J]. JAMA, 2021, 325(4): 353-362.
|
| 22 |
Naidoo A, Naidoo K, Mcilleron H, et al. A Review of moxifloxacin for the treatment of drug-susceptible tuberculosis[J]. J Clin Pharmacol, 2017, 57(11): 1369-1386.
|
| 23 |
薛世民，蒋 伟，贾 娟，等. 莫西沙星治疗老年支原体肺炎患者的临床疗效分析[J]. 现代生物医学进展，2016, 16(18): 3551-3554.
|
| 24 |
肖红雯，彭 勇，周洪伟，等. 血必净注射液联合哌拉西林钠舒巴坦治疗老年重症肺炎的疗效及其对炎性因子和免疫功能的影响[J]. 中国老年学杂志，2021, 41(19): 4218-4221.
|
| 25 |
周 瑜，代艳梅，王一平，等. 老年重症肺炎患者细胞炎性因子、凝血功能情况及预后的影响因素分析[J]. 临床肺科杂志，2020, 25(1): 70-73.
|
| 26 |
许利敏，李 东，李小燕，等. 比阿培南不同滴注时间治疗重症肺炎的疗效与安全性比较[J]. 中国医院用药评价与分析，2019, 19(6): 677-678, 682.
|
| 27 |
沈红卫，麻建平. 老年重症肺炎与sICAM-1、IL-1R1、CD40L及TBX21基因多态性的相关性[J]. 中国老年学杂志，2020, 40(13): 2781-2783.
|
| 28 |
沈晶晶，刘建华，曹 亮. 血清ApoA-I、CD40L、VCAM-1水平与老年SP患者SHG及预后相关性[J]. 分子诊断与治疗杂志，2021, 13(4): 651-654.
|
| 29 |
胡大碧，卢晓静，况 刚，等. 莫西沙星联合用药治疗老年重症肺炎疗效观察及对细菌清除率的影响[J]. 中国药业，2018, 27(15): 64-66.
|
| 30 |
龚 敬，陆 伟，史 刚，等. 比阿培南联合莫西沙星对老年重症肺炎患者炎性指标及不良反应的影响[J]. 河北医学，2020, 26(5): 721-727.
|
| 31 |
Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis？[J]. Am J Respir Crit Care Med, 2008, 178(9): 989-993.
|
| 32 |
Deshpande D, Srivastava S, Nuermberger E, et al. A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME Path on the Milky Way[J]. Clin Infect Dis, 2016, 63(suppl 3): S95-S101.
|